Personalis reports Q4 revenue of $19.7M (+18% YoY); cash runway extended to Q1 2026

Personalis, Inc.

2023-FY EPS reported -$2.25 revenue$73,481,000

Preliminary Q4 revenue $19.7M, up 18% YoY from $16.7M; full-year revenue $73.5M, up 13%.
Natera revenue in Q4 was $7.1M (vs $8.2M prior year); pharma/enterprise/other revenue $18.7M.
Cash and short-term investments $114.0M; cash usage reduced to ~$54M in 2023 from $119M.
Annual cost-cutting reduced expenses by ~$35M; cash runway extended to Q1 2026.
CEO cites NeXT Personal Dx launch, Tempus partnership, and progress on clinical evidence.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Personalis, Inc. reported the fourth quarter ended December 31, 2023 results: revenue $19.7 million.

Period: the fourth quarter ended December 31, 2023
Revenue: $19.7 million
Result: preliminary results

Exact text from the filing

Preliminary total company revenue is estimated to be $19.7 million in the fourth quarter of 2023

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Personalis, Inc. reported the full year ended December 31, 2023 results: revenue $73.5 million.

Period: the full year ended December 31, 2023
Revenue: $73.5 million
Result: preliminary results

Exact text from the filing

Preliminary total company revenue is estimated to be $73.5 million in the full year of 2023

View on SEC.gov

Browse all earnings releases →

Personalis, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-24-002304

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.